Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.
about
Interaction of the tyrosine phosphatase SHP-2 with Gab2 regulates Rho-dependent activation of the c-fos serum response element by interleukin-2Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148Erk5 controls Slug expression and keratinocyte activation during wound healingNucleoporins nup98 and nup214 participate in nuclear export of human immunodeficiency virus type 1 RevMKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathwayExpression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomasActivity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Productive parvovirus B19 infection of primary human erythroid progenitor cells at hypoxia is regulated by STAT5A and MEK signaling but not HIFαConditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cellsErk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth.From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysRegulation of exit from quiescence by p27 and cyclin D1-CDK4.Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation.Integration of signals along orthogonal axes of the vertebrate neural tube controls progenitor competence and increases cell diversityAssociation of mitogen-activated protein kinase with the microtubule cytoskeletonConfluence of vascular endothelial cells induces cell cycle exit by inhibiting p42/p44 mitogen-activated protein kinase activity.Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation.Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways.SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancerInhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinaseMitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo.The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescenceMos activates MAP kinase in mouse oocytes through two opposite pathways.The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal.The extracellular regulated kinase-1 (ERK1) controls regulated alpha-secretase-mediated processing, promoter transactivation, and mRNA levels of the cellular prion protein.The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signalingMitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblastsThe gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity.Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylationMEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1.MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin γ2 expression in oral dysplasia and squamous cell carcinoma.Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expressionThe MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control.Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinaseControl of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells.BRAF inhibitors in clinical oncology.The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.Dynamic regulation of c-Jun N-terminal kinase activity in mouse brain by environmental stimuli.
P2860
Q24294717-217BEE8F-9905-4D02-A7C6-18AE2BA5E639Q24303092-75C22CFF-B43A-4B87-B913-858EF290D6B6Q24324804-67509DF8-01A6-482C-9060-FF00509AC89DQ24516934-022F6578-37DC-42EE-96B3-8C2D3EB158E7Q24650627-8E5C4F14-D199-40F7-9BE6-979447BDDCE6Q24657474-7FBB2898-2164-4AB6-8169-892A30DA7DE7Q27851856-8EAFF2CB-A8AE-4E61-AA56-9D4D0A97D282Q28478598-6F1F8CDB-972A-4EBA-88D5-9DB66289D812Q28609131-C4C1BE82-F7CF-4A96-A95D-BE134E4E6482Q30300846-5E163433-0A72-478F-B018-260ED05A1AB9Q33698374-D91870C0-BEAC-412B-9E41-A9633917982EQ33737298-7C52C6D7-9D54-4B7A-BFE6-B66874E0942BQ33781529-944407A6-0652-43DE-BE5D-E7BB3B7C8C16Q33781714-145388FF-86CB-49A8-BE6E-CFA68E85F29BQ33904021-DF31BFE3-F6B8-4527-8E74-44B511D2A606Q33934584-184DADFD-DB60-4402-8F79-D48A367B0074Q33957717-EBFD2D8A-E0BB-44E7-8D6A-7507208C369BQ33957925-4DCA5E27-E203-49B2-B466-D857441B1F39Q33965685-47F4C332-53AB-419B-AAF6-945F1D4295A3Q34420873-5FA85804-E18A-469E-ACD3-1F6349B347F5Q34452835-302E31C5-6EC7-48BD-A9FB-FA1A70685382Q34473609-C0549620-29AA-4EFA-AE5E-C07AE472744EQ34519801-D6E83CCB-EAF4-4DCD-B5F1-1E33BF7BDC09Q34680511-7B346D6E-BE1E-4C73-B632-7FF2E5176CACQ34699388-60048AC7-DC71-4DA8-8551-B2FB99998DFEQ35310087-3C38FD90-847C-4858-9BC9-3720976413C5Q35544832-D48D96EA-89ED-4A8F-9C1E-C94E45998862Q35648118-28A7E88C-2B04-40E9-97E1-3B156C5169B2Q35722118-353AC74A-4754-4555-BB63-0F76A988764FQ35849279-8DA9C8A3-670B-45D9-A622-FBE8FFED3205Q36041862-A9C36295-9F62-4875-931D-397C071DB5C0Q36044929-B85E4E2A-2D27-4C4C-A918-87F57B42E234Q36236394-4DE331A4-C635-4027-A5D0-5984EF03E0D7Q36362544-3C62D99A-FD40-4F4A-B1A6-E6F88F8EB97CQ36567534-CFF626BF-64C9-499E-A3E6-0166CE38C44CQ36571164-9EFFCC16-6653-403D-A422-978BCCA70CE7Q36626059-F049A1DA-8966-4ACE-B13A-57E016177F7EQ36747050-E8BFE0BE-EF5A-46CC-AD05-1D0CAA86A65DQ36760840-1FDC9953-4642-4290-829F-68DD0FB8654EQ36828179-A20FB102-6FD9-4530-8B0B-65C3716389FF
P2860
Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Constitutively active mutants ...... when expressed in fibroblasts.
@en
Constitutively active mutants of MAP kinase kinase
@nl
type
label
Constitutively active mutants ...... when expressed in fibroblasts.
@en
Constitutively active mutants of MAP kinase kinase
@nl
prefLabel
Constitutively active mutants ...... when expressed in fibroblasts.
@en
Constitutively active mutants of MAP kinase kinase
@nl
P1433
P1476
Constitutively active mutants ...... when expressed in fibroblasts.
@en
P2093
P304
P407
P577
1994-11-01T00:00:00Z